Zoetis valuation resets to 12x forward earnings as growth stalls, but profitability endures

What happened

Zoetis shares have suffered a severe multiyear drawdown, with the company now trading at roughly 12x forward earnings and a nearly 3% dividend yield, a sharp contrast to its historical premium multiple. The growth narrative has broken: competition, weaker U.S. companion animal sales—particularly the osteoarthritis monoclonal antibody franchise—and reduced guidance have pressured revenue and earnings. Despite these headwinds, Zoetis retains core profitability with gross margins above 70%, dominant market share, and a healthy balance sheet despite approximately $9 billion in long-term debt. Management is aggressively repurchasing shares, and capital returns remain strong, signaling confidence in the business's cash generation. However, the market's pessimism reflects real structural concerns, including generic erosion, safety perceptions around Librela, and increased competition, which may keep growth subdued.

Implication

At 12x forward earnings, the market is pricing in a prolonged period of low single-digit growth, but Zoetis's 70%+ gross margins and strong free cash flow provide a buffer against further multiple compression. The aggressive buyback program and near-3% dividend yield offer tangible returns to shareholders while waiting for a growth inflection, but the dividend growth rate has slowed from 16% to 6%, reflecting diminished earnings momentum. Key risks include further regulatory or safety setbacks for Librela, increased competition from Merck and Elanco in dermatology and parasiticides, and macroeconomic pressure on livestock, all of which could delay a recovery. For investors, the stock may be attractive for those with a longer time horizon and tolerance for volatility, but it is not a slam-dunk because the growth story has not yet shown signs of stabilizing. A re-rating could occur if management delivers on Phase IV data for Librela, stabilizes OA mAb sales, and returns to mid-single-digit organic growth, but until then, the stock is likely to remain rangebound.

Thesis delta

The original thesis called for waiting for a better entry or clearer growth inflection. The stock's further decline to a 12x forward P/E and near-3% dividend yield now meets the 'attractive entry' criteria on valuation alone, but the growth deterioration has also worsened, leaving the risk/reward more balanced than outright bullish. We now view Zoetis as a value candidate where the margin of safety has expanded, but conviction remains moderate until there is evidence of stabilization in the OA franchise and overall organic growth.